Log in to save to my catalogue

Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome a...

Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome a...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7417282

Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data

About this item

Full title

Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data

Publisher

London: Nature Publishing Group UK

Journal title

The pharmacogenomics journal, 2020-10, Vol.20 (5), p.724-735

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Current guidelines recommend dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 inhibitors following percutaneous coronary intervention (PCI).
CYP2C19
genotype can guide DAPT selection, prescribing ticagrelor or prasugrel for loss-of-function (LOF) allele carriers (genotype-guided escalation). Cost-effectiveness analyses (CEA)...

Alternative Titles

Full title

Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7417282

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7417282

Other Identifiers

ISSN

1470-269X

E-ISSN

1473-1150

DOI

10.1038/s41397-020-0162-5

How to access this item